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BACKGROUND: Clinical trials show benefit from lowering systolic 
blood pressure (SBP) in people ≥80 years of age, but nonrandomized 
epidemiological studies suggest lower SBP may be associated with higher 
mortality. This study aimed to evaluate associations of SBP with all-
cause mortality by frailty category >80 years of age and to evaluate SBP 
trajectories before death.
METHODS: A population-based cohort study was conducted using 
electronic health records of 144 403 participants ≥80 years of age 
registered with family practices in the United Kingdom from 2001 to 
2014. Participants were followed for ≤5 years. Clinical records of SBP 
were analyzed. Frailty status was classified using the e-Frailty Index into 
the categories of fit, mild, moderate, and severe. All-cause mortality 
was evaluated by frailty status and mean SBP in Cox proportional-
hazards models. SBP trajectories were evaluated using person months 
as observations, with mean SBP and antihypertensive treatment status 
estimated for each person month. Fractional polynomial models were used 
to estimate SBP trajectories over 5 years before death.
RESULTS: During follow-up, 51 808 deaths occurred. Mortality rates 
increased with frailty level and were greatest at SBP <110 mm Hg. 
In fit women, mortality was 7.7 per 100 person years at SBP 120 to 
139 mm Hg, 15.2 at SBP 110 to 119 mm Hg, and 22.7 at SBP <110 
mm Hg. For women with severe frailty, rates were 16.8, 25.2, and 39.6, 
respectively. SBP trajectories showed an accelerated decline in the last 
2 years of life. The relative odds of SBP <120 mm Hg were higher in 
the last 3 months of life than 5 years previously in both treated (odds 
ratio, 6.06; 95% confidence interval, 5.40–6.81) and untreated (odds 
ratio, 6.31; 95% confidence interval, 5.30–7.52) patients. There was 
no evidence of intensification of antihypertensive therapy in the final 2 
years of life.
CONCLUSIONS: A terminal decline of SBP in the final 2 years of life 
suggests that nonrandomized epidemiological associations of low SBP 
with higher mortality may be accounted for by reverse causation if 
participants with lower blood pressure values are closer, on average, to 
the end of life.
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Blood pressure increases with age, and older people have a higher prevalence of hypertension.1,2 Elevat-ed systolic blood pressure (SBP) may be the most 
important risk factor for cardiovascular disease in older 
people.3 Recently, several large clinical trials4–9 have sug-
gested that use of antihypertensive medications to lower 
blood pressure may reduce cardiovascular events and 
mortality in older adults. In HYVET (Hypertension in the 
Very Elderly Trial)6 of antihypertensive therapy >80 years 
of age, lowering blood pressure was associated with 
30% reduction in stroke, 21% reduction in all-cause mor-
tality, and 64% reduction in heart failure. In SPRINT (Sys-
tolic Blood Pressure Intervention Trial),7 in people ≥75 
years of age, management of SBP to a target of <120 
mm Hg was associated with 34% reduction in cardiovas-
cular events and 33% reduction in all-cause mortality. 
These results from clinical trials have prompted renewed 
interest in delivering more intensive management of SBP 
among very old people.
Several nonrandomized epidemiological studies have 
raised concerns about the safety of intensive lowering 
of SBP in people ≥80 years of age. In the Umea co-
hort study of people >85 years of age, baseline SBP of 
<120 mm Hg was associated with substantially higher 
mortality than any other blood pressure category.10 An 
association of higher blood pressure with lower mortal-
ity has been reported in other cohort studies of people 
>7511,12 or >85 years of age.13 These observational find-
ings have led to the suggestion that high blood pres-
sure may not be a risk factor for mortality >85 years 
of age.14 The paradoxical association between lower 
SBP with increased mortality has sometimes been ex-
plained in terms of patients’ frailty, which may confound 
the association of low SBP with mortality in old age.12 
Evidence suggests that SBP levels tend to decline as 
frailty status increases among very old patients,15 sup-
porting future investigations into the modifying effect of 
frailty on the association of SBP with mortality. Frail old-
er adults might also be at risk of adverse outcomes from 
antihypertensive treatment,16 but if they are underrepre-
sented in trial samples, then the results of clinical trials 
might not be generalizable to wider community-dwelling 
populations.17,18 In an analysis of NHANES data (National 
Health and Nutrition Examination Survey), Odden et al19 
found evidence of effect modification according to frailty 
level in terms of walking speed. In fit persons >65 years 
of age, elevated SBP was associated with greater mor-
tality, whereas in frail participants, higher blood pressure 
was associated with lower mortality risk.
This study aimed to investigate the reasons for con-
flicting results from nonrandomized studies and clinical 
trials concerning the prognostic significance of SBP in 
older adults. We conducted longitudinal analyses of pri-
mary care electronic health records data for a large co-
hort of adults ≥80 years of age in the United Kingdom. 
Participants were classified according to frailty level us-
ing a previously reported measure.20 We aimed to evalu-
ate whether the association of SBP with mortality was 
consistent at different levels of frailty, comparing par-
ticipants according to antihypertensive treatment sta-
tus. We also compared SBP trajectories for participants 
who died with those who did not die during 5 years’ 
follow-up.
METHODS
Patient Involvement and Data Source
This study used data from the Clinical Practice Research 
Datalink (CPRD). The CPRD is 1 of the world’s largest data-
bases of primary care electronic health records, including 
≈7% of UK general practices, with anonymized data collected 
from 1990 to present. The registered active population of 
≈5 million is generally representative of the UK population in 
terms of age and sex.21 Data collected into CPRD comprise 
clinical diagnoses, records of blood pressure and other clini-
cal measurements, prescriptions, results of investigations, 
and referrals to specialist services. The protocol for this study 
received scientific and ethical approval from the Independent 
Scientific Advisory Committee for CPRD Studies (ISAC 
Protocol 13_151). The CPRD has broad National Research 
Ethics Service Committee ethics approval for observational 
Clinical Perspective
What Is New?
• Clinical trials suggest that antihypertensive treat-
ment for octogenarians may reduce mortality and 
cardiovascular events, but nonrandomized epidemi-
ological studies generally associate low blood pres-
sure with higher mortality in older adults.
• This article presents data for 144 403 people >80 
years of age living in the United Kingdom.
• The sample was classified by frailty level and antihy-
pertensive treatment status.
• Longitudinal analysis of patients’ blood pressure 
records revealed that a terminal decline occurs in 
systolic blood pressure in the 24 months before 
death, not accounting for changes in antihyperten-
sive treatment. 
What Are the Clinical Implications?
• Clinicians may be concerned by epidemiological 
analyses which suggest that lower systolic blood 
pressure may be associated with higher mortality 
in older adults.
• Recognition that systolic blood pressure may enter 
a phase of terminal decline in the last 24 months of 
life suggests that reverse causation may account 
for nonrandomized epidemiological associations 
of lower SBP with higher mortality because partici-
pants with low blood pressure values may, on aver-
age, be closer to the end of life. 
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research studies. All data were fully anonymized, and individ-
ual consent was not obtained. MG had full access to all the 
data in the study and takes responsibility for its integrity and 
the data analysis.
Study Design and Participants
This research was part of a wider study of aging in the CPRD 
population. For this we drew a random sample of participants 
who had their 80th, 85th, 90th, 95th, and 100th birthdays 
while registered in CPRD between 1990 and 2014, including 
≤50 000 each of men and women, with replacement, in each 
age group. There were <50 000 men and 50 000 women 
eligible in the older age groups, and after accounting for 
participants sampled in >1 age group, the total sample com-
prised 299 495 participants. This procedure enhanced rep-
resentation of older ages in the sample. Participants entered 
the analysis at the age they were sampled, and all analy-
ses were adjusted for age and calendar year. To focus on a 
more recent period, the present analysis was restricted to 
183 425 participants who were registered between January 
1, 2001, and December 31, 2009, with latest follow-up at 
December 31, 2014. After excluding participants who did 
not have ≥1 valid blood pressure records during follow-up, 
144 403 (79%) participants ≥80 years of age had ≥1 blood 
pressure records.
Main Measures
The study analyzed blood pressure measurements recorded 
into participants’ electronic health records at consultations in 
primary care. For each participant, we calculated the mean 
of all systolic and diastolic records recorded within the first 
5 years of follow-up. Participants were divided according to 
their mean SBP values into the categories <110, 110 to 119, 
120 to 139, 140 to 159, and ≥160 mm Hg. Antihypertensive 
drug prescriptions recorded during the first year of follow-up 
were analyzed to determine whether participants were treated 
with antihypertensive medications, which were further classi-
fied into drugs acting on the renin-angiotensin system, includ-
ing angiotensin-converting enzyme inhibitors and angiotensin 
receptor-blocking drugs; β-blockers; calcium channel block-
ers; and thiazide diuretics.22 A further category of other antihy-
pertensive drugs was defined, including centrally acting drugs, 
α-blockers, and vasodilators.
Clinical records were used to determine smoking status,23 
classified into nonsmoker, current smoker, or ex-smoker. Body 
mass index was categorized into underweight (<18.5 kg/m2), 
normal weight (18.5–24.9 kg/m2), overweight (25.0–29.9 
kg/m2), and obese (≥30.0 kg/m2). Serum total cholesterol 
values were grouped into the categories <3.0, 3.0 to 3.9, 
4.0 to 4.9, 5.0 to 5.9, and ≥ 6.0 mmol/L. Indicator variables 
were included for participants with no values recorded. The 
prevalence of comorbidity at the start of the study was deter-
mined from analysis of Read medical codes and drug product 
codes for diabetes mellitus, coronary heart disease, stroke, 
cancer, chronic obstructive pulmonary disease, musculoskel-
etal, and connective tissue diseases and nervous system 
diseases. Multiple morbidity was coded into the categories 
none, 1 to 2, 3 to 4, and ≥5. An index of frailty status was 
calculated for each participant using a previously published 
36-item electronic Frailty Index (eFI).20 The eFI was defined 
based on a cumulative deficit model, which accounts for the 
number of deficits present in an individual.15 The eFI score was 
calculated by the presence or absence of individual deficits as 
a proportion of the total possible based on medical diagnoses 
recorded during the first 12 months of follow-up. Categories 
of fit, mild, moderate, and severe frailty were defined accord-
ing to Clegg et al,20 but the assessment of quantitative traits 
(including blood pressure values) and polypharmacy (includ-
ing antihypertensive medications) were omitted from the 
assessment of frailty because these were key exposures for 
this study. Deaths from any cause were obtained from CPRD 
records. Records were censored after 5 years of follow-up or 
when participants’ CPRD record ended.
Statistical Analysis
Baseline characteristics of study participants were described. 
Time-to-event analyses were conducted to evaluate the asso-
ciation of mean SBP with death from any cause. Mortality 
rates per 100 person years were estimated as measures of 
absolute risk, whereas adjusted hazard ratios were estimated 
using the Cox proportional-hazards model as measures of 
relative risk. The age at which participants were sampled 
was included as a stratification variable. In the model, SBP 
category was the exposure of interest, with SBP 120 to 139 
mm Hg as reference. Analyses were conducted separately 
by sex, frailty category, and antihypertensive treatment sta-
tus. Models were adjusted for age, comorbidity (including 
coronary heart disease, stroke, cancer, chronic obstructive 
pulmonary disorder, musculoskeletal disorders, digestive 
disorders, nervous system disorders, and dementia), total 
cholesterol category, and smoking status. For participants 
receiving antihypertensive medications, analyses were fur-
ther adjusted for the number of classes of antihypertensive 
drugs prescribed and type of drug class. Schoenfeld residu-
als were evaluated to test the proportional-hazards assump-
tion, which was not violated.
To evaluate blood pressure trajectories, we analyzed 
blood pressure records for the same sample of participants. 
We estimated the mean SBP value for each participant month 
for 60 months from 5 years before to death or end of study, 
including all SBP values recorded up to the date of death. 
We also evaluated antihypertensive drug prescribing over 
time and classified each participant month as treated or not 
treated with antihypertensive drugs. We also estimated the 
number of antihypertensive drug classes prescribed in each 
participant month. We used scatter plots, with lowess lines, 
to compare changes in mean SBP values over time for par-
ticipants who died by the end of the study and participants 
who remained alive. We fitted second-order fractional polyno-
mial models using mean SBP values for each participant and 
each month as observations. Models were adjusted for age, 
sex, calendar year, and frailty category. Robust variance esti-
mates were used to account for clustering of observations 
by participant. Models were fitted using the mfp command in 
Stata version 14 (StataCorp LP). Predicted values and their 
confidence intervals were estimated using the fracpred com-
mand. Logistic regression models were fitted using general-
ized estimating equations and robust variance estimates to 
estimate the relative odds of SBP <120 mm Hg by quarter up 
to the date of death.
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RESULTS
Baseline Characteristics
Baseline characteristics of 144 403 eligible participants 
by mean SBP category are shown in Table 1. There 
were 4389 (3.0%) participants with SBP <110 mm Hg 
and 9381 (6.4%) with SBP 110 to 119 mm Hg. There 
were 17 983 (12.5%) with SBP ≥160 mm Hg. Increasing 
frailty was generally associated with lower blood pres-
sure. In those with SBP <110 mm Hg, 22% were fit, 
28% had moderate frailty, and 12% had severe frailty. 
In participants with SBP ≥160 mm Hg, 42% were fit, 
16% had moderate frailty, and 4% had severe frailty. 
Diagnoses of coronary heart disease, stroke, and de-
mentia were more frequent among those with lower SBP 
values. Dementia was diagnosed in 12% of participants 
with SBP <120 mm Hg but only 2% of those with SBP 
≥160 mm Hg. Serum total cholesterol values were gen-
erally lower in those with lower SBP, but there was no 
clear trend in cigarette smoking. Use of antihyperten-
Table 1. Baseline Characteristics of the Study Cohort, by Systolic Blood Pressure Category
 
Characteristics
Systolic Blood Pressure Category (mm Hg)
<110 110–119 120–139 140–159 ≥160
N 4389 9381 53 931 58 719 17 983
Women 2186 (50) 4686 (50) 28 250 (52) 34 453 (59) 12 252 (68)
Age, y 88.0 (5.4) 87.1 (5.4) 85.8 (5.2) 85.1 (4.9) 85.6 (4.9)
Frailty
  Fit 957 (22) 2192 (23) 15 197 (28) 21 129 (36) 7519 (42)
  Mild 1658 (38) 3680 (39) 22 017 (41) 23 581 (40) 6821 (38)
  Moderate 1244 (28) 2479 (26) 12 369 (23) 10 843 (18) 2850 (16)
  Severe 530 (12) 1030 (11) 4348 (8) 3166 (5) 793 (4)
Comorbidity at entry
  Coronary heart disease 1555 (35) 3332 (36) 15 890 (29) 12 870 (22) 3253 (18)
  Stroke 545 (12) 1180 (13) 5637 (10) 4465 (8) 1236 (7)
  Cancer 964 (22) 2044 (22) 11 045 (20) 11 264 (19) 3108 (17)
  Chronic obstructive pulmonary disorder 1040 (24) 2022 (22) 11 142 (21) 10 789 (18) 2932 (16)
  Musculoskeletal 2988 (68) 6527 (70) 39 093 (72) 42 096 (72) 12 208 (68)
  Digestive 2592 (59) 5477 (58) 31 240 (58) 32 200 (55) 8823 (49)
  Nervous system 3077 (70) 6650 (71) 39 057 (72) 41 781 (71) 12 103 (67)
  Dementia 710 (16) 1342 (14) 4500 (8) 2377 (4) 516 (3)
Total cholesterol, mmol/L 4.4 (1.1) 4.5 (1.2) 4.8 (1.2) 5.1 (1.2) 5.4 (1.2)
Diastolic blood pressure, mm Hg 63 (10) 69 (10) 74 (10) 79 (10) 84 (12)
Smoking status
  Nonsmoker 1340 (31) 3445 (37) 22 759 (42) 27 304 (47) 8211 (46)
  Current smoker 517 (12) 1351 (14) 8359 (16) 8624 (15) 2189 (12)
  Ex-smoker 732 (17) 1904 (20) 12 030 (22) 12 522 (21) 3281 (18)
  Not recorded 1800 (41) 2681 (29) 10 783 (20) 10 269 (17) 4302 (24)
Antihypertensive medications* 2141 (49) 4898 (52) 31 912 (59) 37 258 (63) 11 264 (63)
Renin angiotensin system medications† 1476 (69) 3064 (63) 17 136 (54) 18 297 (49) 5531 (49)
Beta-blockers† 676 (32) 1745 (36) 10 764 (34) 12 578 (34) 4308 (38)
Calcium channel blockers† 482 (23) 1425 (29) 12 633 (40) 16 091 (43) 4704 (42)
Diuretics† 332 (16) 1021 (21) 10 502 (33) 17 320 (46) 5943 (53)
Other antihypertensive† 86 (4) 287 (6) 2591 (8) 4075 (11) 1701 (15)
Values are mean±SD or n (%).
*Drugs prescribed in first 12 months of patients’ record.
†Percentage of participants treated with antihypertensive drugs.
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sive medications was generally more frequent in those 
with higher SBP values.
Mortality and SBP
There were 51 808 deaths during follow-up. Tables 2 
and 3 presents mortality rates per 100 person years 
by frailty, SBP category, and antihypertensive treat-
ment status. Mortality increased with increasing frail-
ty category. At each level of frailty, mortality rates 
were lowest among participants with SBP 140 to 159 
mm Hg, whereas for participants with SBP 100 to 119 
mm Hg, mortality rates were more than twice as high, 
and for participants with SBP <110 mm Hg, mortality 
was >3 times as high. The results were similar among 
those who were treated with antihypertensive medica-
tions and those who were not on treatment. The data 
reveal that 340/7221 (5%) of treated patients with se-
vere frailty and 285/22 224 (1%) of fit patients had SBP 
records <110 mm Hg.
To address confounding and the influence of anti-
hypertensive treatment, adjusted hazard ratios for the 
association of SBP category with mortality were esti-
mated separately by antihypertensive treatment sta-
tus for men and women and for each frailty category 
(Table 4 and 5). Analyses were adjusted for diastolic 
blood pressure, age and comorbidity, total cholesterol, 
and smoking status. In men and women, there was a 
greater relative hazard for SBP 110 to 119 or <110 
mm Hg compared with SBP 120 to 139 mm Hg as a 
reference category. This association was observed in 
both participants treated with antihypertensive drugs 
and untreated participants. Hazard ratios were higher 
for SBP <110 mm Hg than for SBP 110 to 119 mm Hg. 
Hazard ratios for a given SBP category were gener-
ally consistent across frailty categories. Hazard ratios 
were generally lower for SBP 140 to 159 mm Hg than 
the reference category. SBP ≥160 mm Hg was not gen-
erally associated with higher relative hazard, except in 
men with severe frailty. When 10 mm Hg SBP catego-
ries were used for analysis of the sample as a single 
group, the hazard ratio for SBP 130 to 139 mm Hg, 
compared with 120 to 129 mm Hg as reference, was 
0.82 (0.79–0.84).
Table 2. Number of Deaths and Mortality Rates 
per 100 Person Years for Patients Not Treated With 
Antihypertensive Medications, by Systolic Blood 
Pressure and Frailty Category
Frailty 
Category
Systolic Blood Pressure Category (mm Hg)
<110 110–119 120–139 140–159 ≥160
Fit
  n 672 1478 8463 10 350 3807
  Mean age, y 88.2 86.9 85.5 84.6 84.8
  Deaths 413 703 2696 2248 833
  Rate 20.3 13.4 8.0 5.1 5.3
Mild
  n 846 1742 8510 7491 2080
  Mean age, y 88.8 88.3 86.8 86.0 86.7
  Deaths 608 1046 3607 2326 685
  Rate 28.6 19.6 11.8 8.1 9.0
Moderate 
  n 540 941 3860 2832 672
  Mean age, y 89.3 88.5 87.7 87.5 88.3
  Deaths 432 631 1892 1203 309
  Rate 40.3 25.5 15.3 12.6 14.7
Severe
  n 190 322 1186 788 160
  Mean age, y 89.1 88.7 88.4 88.1 88.4
  Deaths 162 233 713 409 87
  Rate 47.9 32.3 20.7 18.0 22.5
Table 3. Number of Deaths and Mortality Rates 
per 100 Person Years for Patients Treated With 
Antihypertensive Medications, by Systolic Blood 
Pressure and Frailty Category
Frailty 
Category
Systolic Blood Pressure Category (mm Hg)
<110 110–119 120–139 140–159 ≥160
Fit
  n 285 714 6734 10 779 3712
  Mean age, y 87.5 86.3 84.5 83.9 84.6
  Deaths 185 355 2064 2307 917
  Rate 22.7 15.2 7.7 5.1 6.3
Mild 
  n 812 1938 13 507 16 090 4741
  Mean age, y 87.5 86.1 85.1 84.7 85.6
  Deaths 599 1036 4864 4322 1506
  Rate 31.9 16.7 9.7 6.8 8.7
Moderate 
  n 704 1538 8509 8011 2178
  Mean age, y 86.8 86.6 85.9 85.6 86.5
  Deaths 522 942 3696 2717 848
  Rate 33.8 21.9 12.7 9.3 11.6
Severe 
  n 340 708 3162 2378 633
  Mean age, y 87.6 86.7 86.6 86.5 87.1
  Deaths 267 469 1643 1020 293
  Rate 39.6 25.2 16.8 13.1 16.1
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SBP Trajectories
To clarify the association of SBP with mortality, we plot-
ted the mean of SBP values recorded by month from 
5 years before death or end of study (Figure 1). Data 
are presented for 144 403 participants in total. There 
was a mean of 16 970 (range 10 610–26 464) partici-
pants contributing data in any single month. Individual 
participants contributed data in a mean of 7 months 
(range 1–58 months). Figure 1, Left shows that mean 
SBP values declined over time. This decline was more 
rapid among participants who died than in those who 
did not die during the study. In the last 12 to 24 months 
of life, the decline in SBP accelerated, with SBP val-
ues being ≈15 mm Hg lower at the end of the period 
than at the beginning. SBP values were initially higher 
in participants who were treated with antihypertensive 
medications, but a terminal decline in SBP values be-
fore death was observed in both treated and untreated 
participants.
Fractional polynomial models were fitted separately 
for participants who died or did not die by antihyper-
tensive treatment status (Figure 1, Right, and Table I in 
the online-only Data Supplement). Fractional polynomial 
models were adjusted for sex, age, frailty category, and 
calendar year. The fractional polynomial plots (Figure 1, 
Right) confirm an accelerated decline in SBP in the last 
24 months of life. In a logistic regression analysis, the 
relative odds of SBP <120 mm Hg were higher in the last 
3 months of life than 5 years previously in both treated 
(odds ratio, 6.06; 95% confidence interval, 5.40–6.81) 
and untreated patients (odds ratio, 6.31; 95% confi-
dence interval, 5.30–7.52). (Figure I in the online-only 
Data Supplement).
Additional Information and Sensitivity Analyses
Table 6 shows data for blood pressure recording and 
antihypertensive therapy for deceased and surviving par-
ticipants by year. Participants who died during the 5-year 
study period necessarily had shorter overall follow-up 
than those who survived. The proportion of participants 
with ≥1 blood pressure readings in each year was gen-
erally slightly higher among surviving participants than 
those who died (P<0.001). Surviving participants also 
tended to have more frequent blood pressure readings 
than those who died. We noted that the number of blood 
pressure readings available for analysis was associated 
Table 4. Association of Systolic Blood Pressure Category With All-Cause Mortality for Patients Not Treated 
With Antihypertensive Medications, by Frailty Category, Sex, and Antihypertensive Treatment
Systolic Blood 
Pressure Category 
(mm Hg)
Fit Mild Moderate Severe 
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Men
  <110 1.71  
(1.42 to 2.05)
<0.001
1.96  
(1.66‒2.30)
<0.001
2.05  
(1.69‒2.47)
<0.001
1.78  
(1.21‒2.64)
0.004
  110–119 1.29  
(1.13‒1.47)
<0.001
1.47  
(1.31 to 1.65)
<0.001
1.58  
(1.36‒1.84)
<0.001
1.39  
(1.06‒1.82)
0.015
  120–139 Reference Reference Reference Reference
  140–159 0.83  
(0.76‒0.90)
<0.001
0.85  
(0.78‒0.92)
<0.001
0.88  
(0.77‒1.00)
0.052
1.28  
(1.01‒1.61)
0.039
  ≥160 0.87  
(0.76‒0.99)
0.029
1.01  
(0.87‒1.17)
0.876
1.15  
(0.91‒1.46)
0.239
2.32  
(1.57‒3.45)
<0.001
Women
  <110 1.63  
(1.35‒1.95)
<0.001
1.61  
(1.38‒1.88)
<0.001
2.11  
(1.77‒2.53)
<0.001
2.00  
(1.55‒2.58)
<0.001
  110–119 1.26  
(1.10‒1.44)
0.001
1.24  
(1.12‒1.39)
<0.001
1.43  
(1.25‒1.64)
<0.001
1.47  
(1.20‒1.82)
<0.001
  120–139 Reference Reference Reference Reference
  140–159 0.73  
(0.67‒0.80)
<0.001
0.80  
(0.74‒0.87)
<0.001
0.90  
(0.82‒0.99)
0.039
0.85  
(0.72‒1.01)
0.062
  ≥160 0.82  
(0.72‒0.92)
0.001
0.81  
(0.72‒0.92)
0.001
0.93  
(0.79‒1.11)
0.423
0.79  
(0.56‒1.11)
0.176
Values are adjusted for age, diastolic blood pressure, comorbidity, total cholesterol, smoking, and antihypertensive treatment. CI indicates confidence 
interval; and HR, hazard ratio. 
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with both the mean SBP category and the level of frailty 
(Table II in the online-only Data Supplement). Among fit 
participants, the median number of BP readings per 
participant year ranged from 0.8 to 1.8, whereas for 
participants with severe frailty, the median number of BP 
readings per year ranged from 2.3 to 3.0. However, SBP 
trajectories were similar for participants who had had 
either more, less than, or equal to the mean number of 7 
participant months with SBP values recorded (Figure II in 
the online-only Data Supplement). There was no evidence 
that patients who died received more intense antihyper-
tensive therapy. Surviving participants included a slightly 
lower proportion not prescribed antihypertensive drugs, 
with higher proportions prescribed ≥2 classes of antihy-
pertensive drugs (P<0.001). Antihypertensive drug pre-
scribing increased over the period (P<0.001), but there 
was only weak evidence for a difference in trend accord-
ing to whether patients survived (P=0.042). There was 
no evidence for intensification of antihypertensive thera-
py in the final months of life. When participants who died 
within 6 months of study entry were excluded from the 
analysis, there was no difference in interpretation (Table 
III in the online-only Data Supplement).
DISCUSSION
Main Findings
In this large cohort of individuals ≥80 years of age, SBP 
<120 mm Hg was associated with greater risk of mortal-
ity in both men and women when compared with SBP of 
120 to 139 mm Hg. The level of frailty was classified 
from data recorded into primary care electronic health 
records. Mortality was higher in more frail participants, 
whereas the association of SBP <120 mm Hg with mor-
tality was consistently observed at each level of frailty. 
The proportion of treated patients with SBP <110 mm Hg 
increased with frailty level, which might indicate over-
treatment in some cases. Longitudinal analysis of partici-
pants’ blood pressure records revealed a secular decline 
in SBP,24 but participants who die experience an acceler-
ated decline in SBP in the final 24 months of life. These 
last months of life are associated with greatly increased 
A
C
B
D
Figure 1. Trajectory of systolic blood pressure during 60 months before death (red) or end of study (blue).  
Left, Mean SBP by month: (A) squares, not treated; (C) circles, treated with antihypertensive medications. Right, Predictions 
(95% confidence intervals) from multiple fractional polynomial model adjusted for age, sex, calendar year, and frailty category: 
(B) not treated; (D) treated with antihypertensive medications.
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odds of low SBP recordings. These observations may 
account for the discrepancy between clinical trial results, 
which provide evidence of benefit from blood pressure 
lowering, as compared with nonrandomized studies, 
which generally associate lower SBP with higher mortal-
ity. Randomization will ensure that comparison groups 
are, on average, similar with respect to underlying risk 
of mortality; in nonrandomized studies, reverse causa-
tion may apply if lower SBP values are accounted for by 
proximity to death. Changes in SBP before death were 
generally similar in participants who were treated or not 
treated with antihypertensive drugs. Analysis of blood 
pressure recording and prescription of antihypertensive 
drugs revealed no evidence to suggest that there might 
be intensification of antihypertensive therapy to account 
for lower blood pressure before death. Participants who 
survived to the end of the study period had more fre-
quent blood pressure recordings and were more likely to 
be treated with multiple antihypertensive drug classes.
Strengths and Limitations
The study has the strengths of a large sample of older 
adults with comprehensive data for medical diagnoses 
and drug treatment. The eligibility criteria were unrestrict-
ed, and the sample may have included nonambulatory 
patients as well as those with dementia or living in nurs-
ing homes. These groups of patients are often excluded 
from clinical trials. Blood pressure measurements were 
recorded in clinical practice using possibly nonstandard-
ized methods, with no regularity of measurements over 
time in individual participants. Blood pressure measure-
ments in the clinic may be higher than usual ambulatory 
values25 and may also be appreciably higher than those 
recorded in clinical trials. In SPRINT, a 5-minute rest pe-
riod was observed for all BP measurements.7,26 We did 
not have information concerning resting time, position, 
cuff size, device type, number of measurements, or 
whether orthostatic BP measurements were recorded. 
Despite these limitations, analysis of measurements 
routinely recorded in primary care may closely resemble 
those encountered by physicians in their usual practice.
The effect of misclassification of blood pressure will 
generally be to reduce the strength of reported asso-
ciations. We did not have sufficient data concerning the 
dosage of antihypertensive medications. It may also be 
noted that, although information on prescription might 
be available, we cannot guarantee administration of the 
drugs. There were also missing and possibly misclassi-
fied values for important covariates, including smoking, 
which might lead to bias. There is no consensus on the 
definition of the frailty syndrome, and different opera-
tional tools have been used to measure this condition.27 
Studies comparing different models suggest that most 
Table 5. Association of Systolic Blood Pressure Category With All-Cause Mortality for Patients Treated With 
Antihypertensive Medications, by Frailty Category, Sex, and Antihypertensive Treatment
Systolic Blood 
Pressure Category 
(mm Hg)
Fit Mild Moderate Severe 
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Men
  <110 2.02  
(1.54‒2.66)
<0.001
2.51  
(2.16‒2.91)
<0.001
2.00  
(1.71‒2.33)
<0.001
1.62  
(1.25‒2.09)
<0.001
  110–119 1.54  
(1.30‒1.83)
<0.001
1.45  
(1.32‒1.60)
<0.001
1.44  
(1.29‒1.61)
<0.001
1.31  
(1.11‒1.53)
0.001
  120–139 Reference Reference Reference Reference
  140–159 0.78  
(0.71‒0.85)
<0.001
0.83  
(0.78‒0.88)
<0.001
0.89  
(0.82‒0.96)
0.004
0.89  
(0.77‒1.03)
0.112
  ≥160 0.98  
(0.85‒1.13)
0.748
1.04  
(0.94‒1.16)
0.436
1.18  
(1.01‒1.37)
0.028
1.21  
(0.90‒1.63)
0.212
Women
  <110 1.86  
(1.39‒2.47)
<0.001
1.98  
(1.67‒2.35)
<0.001
2.34  
(1.98‒2.77)
<0.001
1.98  
(1.53‒2.56)
<0.001
  110–119 1.48  
(1.23‒1.79)
<0.001
1.46  
(1.30‒1.63)
<0.001
1.55  
(1.38‒1.75)
<0.001
1.44  
(1.24‒1.70)
<0.001
  120–139 Reference Reference Reference Reference
  140–159 0.76  
(0.70‒0.84)
<0.001
0.79  
(0.74‒0.84)
<0.001
0.81  
(0.75‒0.87)
<0.001
0.80  
(0.72‒0.89)
<0.004
  ≥160 0.85  
(0.75‒0.96)
0.011
0.91  
(0.83‒1.00)
0.068
0.95  
(0.86‒1.06)
0.401
0.97  
(0.82‒1.15)
0.733
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tools used to assess frailty are strongly associated with 
adverse outcomes, including mortality.28,29 The Frailty 
phenotype30 and the eFI31 are the 2 most widely used 
frailty models. We used a deficit accumulation model to 
assess frailty, whereas the Frailty Phenotype includes 
physical measures of frailty, such as walking speed, grip 
strength, low physical activity, and weight loss. Studies 
comparing these models have shown that they both pre-
dict adverse outcomes, but different frailty models might 
not necessarily identify the same individuals as frail.32 It 
is also important to emphasize that physical measures 
may be difficult to complete in the very old because of 
their poor health and possible inability to participate.33 
The eFI is based on clinical diagnoses and records of 
age-related impairments that impact physical and mental 
functioning. We assumed that items not recorded were 
absent, but clinical records may sometimes have low 
sensitivity for age-related impairments, especially when 
these are in their early stages. For example, the preva-
lence of clinical dementia diagnosis in this sample is al-
most certainty an underestimate of the condition’s true 
prevalence. Both the Frailty phenotype and the deficit ac-
cumulation approach may predict adverse outcomes, but 
there may be differential classification of individuals.34 We 
did not have data concerning gait speed or other objec-
tive physical function measures, and it should be noted 
that lack of objective measures of functional problems, 
including cognitive function, may be a limitation of the 
eFI. However, assessment of physical function across dif-
ferent primary care practices might result in bias from 
misclassification. The eFI addresses activity limitations 
and cognitive functioning through the analysis of physi-
cian recorded diagnostic codes. We excluded blood pres-
sure measurements from estimation of the eFI, but we 
did not exclude clinical diagnoses of hypotension, hyper-
tension, and dizziness, which contribute to the 36 deficits 
contained in the eFI. This finding implies that hypertensive 
individuals may be classified as slightly more frail, but 
we analyzed frailty in broad categories as recommended 
by the scale developers. We compared SBP trajectories 
of participants who died with those who survived to the 
end of the study, but associations might be diminished if 
the surviving patients were also nearing the end of their 
lives. During the period of study, there were changes in 
antihypertensive drug utilization in this population, with 
declining use of diuretics and increasing use of drugs act-
ing on the renin-angiotensin system and calcium channel 
blockers.24 Secular declines also occurred in SBP24 and 
mortality.35 More people are living to older ages but often 
with greater comorbidity.36 We caution that associations 
might differ in future periods of time.
Comparison With Previous Research
In HYVET6 of antihypertensive therapy >80 years of age, 
blood pressure lowering was associated with substantial 
Table 6. Changes in Blood Pressure and Antihypertensive Therapy 5 Years Before Death
Years 
Before 
Death or 
End of 
Study
At Risk 
in Year, n
With ≥1  
Blood Pressure 
Reading in  
Year, n (%)
Mean 
Number 
of Months 
With Blood 
Pressure 
Readings*
Systolic 
Blood 
Pressure, 
Mean (SD)
Number of Antihypertensive Drug Classes Prescribed in Year
0 1 2 3 4+
Alive
  –5 70 954 52 379 (74) 2.5 145.4 (17) 27 759 (39) 18 402 (26) 15 793 (22) 7140 (10) 1860 (3)
  –4 76 716 58 513 (76) 2.5 144.3 (17) 28 096 (37) 20 333 (27) 17 884 (23) 8104 (11) 2299 (3)
  –3 82 816 65 181 (79) 2.4 142.9 (17) 29 221 (35) 22 627 (27) 19 691 (24) 8808 (11) 2469 (3)
  –2 88 879 72 285 (81) 2.4 141.5 (17) 30 492 (34) 24 982 (28) 21 202 (24) 9545 (11) 2658 (3)
  –1 92 554 77 463 (84) 2.3 139.6 (17) 31 168 (34) 26 697 (29) 22 320 (24) 9831 (11) 2538 (3)
Died†
  –5 8131 4147 (51) 1.8 144.5 (20) 3612 (44) 2332 (29) 1513 (19) 529 (7) 145 (2)
  –4 18 309 11 567 (63) 2.1 142.7 (19) 7646 (42) 5494 (30) 3557 (19) 1299 (7) 313 (2)
  –3 29 425 20 556 (70) 2.1 140.6 (19) 11 795 (40) 9077 (31) 5875 (20) 2169 (7) 509 (2)
  –2 39 830 31 258 (78) 2.1 138.3 (20) 15 418 (39) 12 724 (32) 8047 (20) 2977 (7) 664 (2)
  –1 43 133 36 679 (85) 2.3 133.6 (19) 16 153 (37) 14 074 (33) 8970 (21) 3212 (7) 724 (2)
Values are n (%), except where indicated.
*Mean number of months in year with blood pressure values were recorded for participants with 1 or more readings.
†Person-time was eligible for analysis from January 1, 2010, to December 3, 2014. Participants who died during this period necessarily had shorter 
duration of follow-up overall.
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reduction in stroke, all-cause mortality, and heart failure. 
In SPRINT7 in people ≥75 years of age, management 
of SBP to a target of <120 mm Hg was associated with 
reduction in cardiovascular events and all-cause mortal-
ity. To address concerns that the trial samples may not 
have been representative, each of these clinical trials 
conducted analyses to show that the main findings were 
consistent across frailty categories.17,18
Several previous observational studies showed a 
negative association of increased blood pressure and 
mortality in the very old.2,13,14,37,38 A report from EPESE 
(the Established Populations for Epidemiological Stud-
ies of the Elderly)13 found that in younger elderly indi-
viduals 65 to 84 years of age, there was a positive 
association between SBP and mortality even after ad-
justing for comorbidities, whereas in men ≥85 years 
of age, higher SBP was associated with lower mortal-
ity. In women ≥85 years of age, there was no associa-
tion between SBP and mortality.13 Rastas et al39 found 
that SBP <140 mm Hg was associated with higher all-
cause mortality in all men and women after adjusting 
for confounders. In the Umea 85+ study, low SBP was 
associated with greater mortality even after adjustment 
for preexisting comorbidity and frailty.10,39 Although it 
has been suggested that the association between low 
blood pressure and mortality might be an indicator of 
a greater disease burden and a marker of poor health, 
our results show that low SBP is associated with mor-
tality even in fit participants. The results from a popula-
tion study by Nilsson et al40 in those ≥80 years of age 
showed that low SBP was associated with an increased 
risk of cognitive decline irrespective of frailty status. 
In the PARTAGE study (Predictive Values of Blood Pres-
sure and Arterial Stiffness in Institutionalized Very Aged 
Population) of institutionalized older adults ≥80 years 
of age, there was effect modification from antihyper-
tensive treatment. Participants with low SBP (<130 
mm Hg) receiving ≥2 antihypertensive drugs were at 
increased risk of mortality compared with the group 
receiving either 1 or no antihypertensive drugs. This 
study included an institutional sample that may differ 
from our community dwelling sample, and differing defi-
nitions of antihypertensive treatment were used.41 Anal-
ysis of NHANES data suggested that the association 
of lower BP with greater mortality was most evident in 
frail participants.19 In the present study, mortality rates 
were elevated for lower blood pressures at all levels of 
frailty. These differences might be explained by differ-
ing participant selection and choice of frailty classifi-
cation. Considering the totality of evidence, a system-
atic review suggested that less aggressive treatment 
would be an optimal approach in treating hypertension 
in older adults.42 A review exploring the management of 
hypertension in those ≥80 years of age suggested that 
individualized treatment plans should be designed when 
treating frail older adults.43
Kalantar-Zadeh et al44 noted that lower SBP values 
have been associated with higher mortality in patients 
with heart failure and end-stage renal failure45 and offered 
several explanations for this finding. People who live to 
advanced ages or advanced disease states are necessar-
ily highly selected with the consequence that survivor bias 
may contribute to patterns of association that differ from 
those observed in the general population.44 The temporal 
pattern of exposure may also be important if higher blood 
pressure confers a short-term survival advantage in the 
final months of life.44 Deteriorating nutritional status, ac-
companied by chronic inflammation, may also tend to 
lower blood pressure levels at the end of life.44
Our results suggest that a substantial decline in 
blood pressure may be a recognizable feature of the 
final stages of life, at least in the final 2 years, with 
lower SBP often being a marker of proximity to death. 
Accelerated functional decline before death was noted 
by Diehr et al46 in data from the Cardiovascular Health 
Study. This decline is sometimes referred to as ter-
minal decline or terminal drop.47 Terminal decline has 
been described previously with respect to cognitive 
function48 and subjective health measures49 but not 
blood pressure.
CONCLUSIONS
In nonrandomized data for people >80 years of age, 
SBP <120 mm Hg is associated with higher mortality 
irrespective of frailty status, sex, or antihypertensive 
treatment. This association may be explained in part 
by a terminal decline of SBP, which is observed in the 
final 2 years of life. These observations may account 
for the discrepancy between randomized and nonran-
domized studies of SBP and mortality in people >80 
years of age. Reverse causation may apply if lower 
SBP values result from proximity to death. The present 
data may not provide an explanation for BP-outcome 
associations <2 years before death. Whether the ob-
servation of more favorable outcomes with higher SBP 
for >2 years before death is true or confounded re-
mains uncertain. Consequently, it may be inadvisable 
to base blood pressure treatment recommendations 
on nonrandomized data for effectiveness outcomes. 
We noted SBP values <110 mm Hg in a minority of 
treated patients, which suggests that reducing the in-
tensity of antihypertensive therapy may sometimes be 
important in this age group.
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1 
 
SUPPLEMENTARY MATERIAL 
 
Supplementary Table 1: Estimates from multiple fractional polynomial (FP) models.  
Status Antihypertensive 
medications 
Powers selected Coefficients for month before end 
 First Second First term Second term 
      
Died Not treated -0.5 3 2.56 (0.59) -0.05 (0.002) 
      
Alive Not treated 0 2 -0.55 (0.09) -0.19 (0.008) 
      
Died Treated 3 3 0.02 (0.02) -0.05 (0.01) 
      
Alive Treated 0 2 -1.10 (0.06) -0.14 (0.005) 
      
Coefficients for month before death or end of study were adjusted for age and calendar year (both as second-
degree FP) and frailty category and gender. 
 
 
 
  
2 
 
Supplementary Figure 1: Relative odds of SBP 120 mm Hg by quarter before death or 
end of study by antihypertensive treatment status. Left panel, not treated with 
antihypertensive drugs; right panel, treated with antihypertensive drugs.  
 
 
 
 
Figures are odds ratios (95% confidence intervals). Red symbols, participants who died; blue symbols, 
participants who did not die. 
 
 
 
 
 
 
 
 
3 
 
Supplementary Table 2. Rate of BP recordings by frailty and systolic blood pressure 
categories.  
 Systolic BP category (mm Hg) 
Frailty category <110 110-119 120-139 140-159 ≥160 
Fit 0.84 1.00 1.20 1.67 1.80 
Mild 1.44 1.54 1.75 2.20 2.60 
Moderate 1.92 1.94 2.00 2.55 2.82 
Severe 2.34 2.32 2.40 2.73 3.04 
Figures are median number of BP readings per patient year. 
 
  
4 
 
Supplementary Figure 2: Systolic blood pressure trajectories by level of BP recording.  
 
 
 
 
Figures were plotted for participants with more than the mean, or less than or equal to the mean number of 
participant months contributing data.  
5 
 
Supplementary Table 3: Association of SBP category with all-cause mortality by frailty category, gender and anti-hypertensive treatment. Participants 
that died within six months of study entry were excluded.  
 SBP category 
(mm Hg) 
‘Fit’ ‘Mild frailty’ ‘Moderate frailty’ ‘Severe frailty’ 
 HR (95% CI) P value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value 
         
   Not Treated with Antihypertensive Medications    
Men <110 1.66 (1.38 to 2.00) <0.001 1.86 (1.57 to 2.20) <0.001 2.03 (1.66 to 2.47) <0.001 1.90 (1.25 to 2.87) 0.003 
110-119 1.27 (1.11 to 1.45)  <0.001 1.46 (1.30 to 1.65) <0.001 1.60 (1.37 to 1.88) <0.001 1.45 (1.10 to 1.93) 0.008 
 120-139 Reference Reference Reference Reference 
 140-159 0.82 (0.76 to 0.89) <0.001 0.83 (0.76 to 0.91) <0.001 0.86 (0.75 to 0.98) 0.023 1.17 (0.92 to 1.49) 0.191 
 ≥160 0.86 (0.75 to 0.97)   0.018 0.98 (0.85 to 1.14) 0.842 1.09 (0.85 to 1.40) 0.494 2.11 (1.31 to 3.17) <0.001 
 
       
Women <110 1.49 (1.23 to 1.80) <0.001 1.53 (1.31 to 1.79) <0.001 2.03 (1.68 to 2.45) <0.001 1.99 (1.51 to 2.61) <0.001 
 110-119 1.24 (1.07 to 1.42)  0.002 1.23 (1.10 to 1.37)  <0.001 1.41 (1.22 to 1.62)  <0.001 1.38 (1.11 to 1.72)  0.003 
 120-139 Reference Reference Reference Reference 
 140-159 0.72 (0.66 to 0.79) <0.001 0.78 (0.72 to 0.84) <0.001 0.90 (0.82 to 1.00) 0.050 0.82 (0.69 to 0.97) 0.020 
 ≥160 0.81 (0.72 to 0.92)   0.001 0.78 (0.69 to 0.88)  <0.001 0.89 (0.75 to 1.06) 0.198 0.77 (0.54 to 1.10) 0.149 
   Treated with Antihypertensive Medications   
Men <110 1.93 (1.46 to 2.55) <0.001 2.38 (2.05 to 2.77) <0.001 1.97 (1.68 to 2.31) <0.001 1.58 (1.21 to 2.06)    0.001 
110-119 1.55 (1.30 to 1.85) <0.001 1.45 (1.32 to 1.60) <0.001 1.47 (1.31 to 1.65) <0.001 1.35 (1.15 to 1.60)  <0.001 
 120-139 Reference Reference Reference Reference 
 140-159 0.78 (0.71 to 0.85)  <0.001 0.82 (0.76 to 0.87) <0.001 0.88 (0.80 to 0.95)  0.002 0.86 (0.74 to 1.00) 0.049 
 ≥160 0.95 (0.82 to 1.10) 0.501 1.02 (0.91 to 1.14)  0.724 1.14 (0.98 to 1.32) 0.094 1.17 (0.86 to 1.57) 0.317 
 
        
Women <110 1.86 (1.38 to 2.50) <0.001 2.14 (1.81 to 2.54) <0.001 2.24 (1.88 to 2.66) <0.001 1.95 (1.50 to 2.54)  <0.001 
110-119 1.46 (1.21 to 1.77) <0.001 1.51 (1.34 to 1.69) <0.001 1.51 (1.33 to 1.70) <0.001 1.43 (1.21 to 1.68) <0.001 
 120-139 Reference Reference Reference Reference 
 140-159 0.76 (0.70 to 0.84) <0.001 0.80 (0.75 to 0.85) <0.001 0.81 (0.75 to 0.87)  <0.001 0.77 (0.69 to 0.86) <0.001 
 ≥160 0.84 (0.74 to 0.95)  0.007 0.91 (0.83 to 1.00) 0.059 0.94 (0.85 to 1.05)  0.304 0.91 (0.76 to 1.09)   0.313 
          
Figures are hazard ratios (HR) and 95% confidence intervals adjusted for age, diastolic blood pressure, comorbidity, total cholesterol, smoking and anti-hypertensive treatment. 
